Yes, ICAM-1 is a potential target for therapeutic intervention. Blocking ICAM-1 interactions can reduce leukocyte adhesion and migration, thereby alleviating inflammation. Monoclonal antibodies and small molecules targeting ICAM-1 or its ligands are being explored in preclinical and clinical studies for various inflammatory conditions.
